プロスタグランジンE2受容体EP4サブタイプ治療薬市場:パイプラインレビュー(2019年下半期)

【英語タイトル】Prostaglandin E2 Receptor EP4 Subtype - Pipeline Review, H2 2019

Global Markets Directが出版した調査資料(GDATA20MY0150)・商品コード:GDATA20MY0150
・発行会社(調査会社):Global Markets Direct
・発行日:2019年11月25日
・ページ数:64
・レポート言語:英語
・レポート形式:PDF
・納品方法:Eメール
・調査対象地域:グローバル
・産業分野:製薬
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD3,500 ⇒換算¥367,500見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD7,000 ⇒換算¥735,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD10,500 ⇒換算¥1,102,500見積依頼/購入/質問フォーム
販売価格オプションの説明
※お支払金額:換算金額(日本円)+消費税
※納期:即日〜2営業日(3日以上かかる場合は別途表記又はご連絡)
※お支払方法:納品日+5日以内に請求書を発行・郵送(請求書発行日より2ヶ月以内に銀行振込、振込先:三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能)
【レポートの概要】

Prostaglandin E2 Receptor EP4 Subtype – Pipeline Review, H2 2019
Summary

Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4) pipeline Target constitutes close to 15 molecules. Out of which approximately 14 molecules are developed by companies and remaining by the universities/institutes. The latest report Prostaglandin E2 Receptor EP4 Subtype – Pipeline Review, H2 2019, outlays comprehensive information on the Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4) – Prostaglandin E2 receptor 4 (EP4) is a prostaglandin receptor encoded by the PTGER4 gene. The activity of the receptor is mediated by G proteins that stimulate adenylate cyclase. It has a relaxing effect on smooth muscle. It plays an important role in regulating renal hemodynamics, intestinal epithelial transport, adrenal aldosterone secretion, and uterine function. The molecules developed by companies in Phase II, Phase I, Preclinical and Discovery stages are 5, 1, 6 and 2 respectively. Similarly, the universities portfolio in Discovery stages comprises 1 molecules, respectively.

Report covers products from therapy areas Oncology, Central Nervous System, Gastrointestinal, Genetic Disorders, Immunology, Women’s Health, Musculoskeletal Disorders and Respiratory which include indications Breast Cancer, Endometriosis, Gastric Cancer, Inflammatory Pain, Liver Cancer, Lung Cancer, Pain, Prostate Cancer, Allergies, Arthritis Pain, Autoimmune Disorders, Chronic Obstructive Pulmonary Disease (COPD), Colon Cancer, Colorectal Cancer, Esophageal Cancer, Familial Adenomatous Polyposis, Gastrointestinal Tract Cancer, Head And Neck Cancer, Hepatocellular Carcinoma, Inflammatory Bowel Disease, Metastatic Colorectal Cancer, Non-Small Cell Lung Cancer, Osteoarthritis Pain, Osteogenesis Imperfecta, Osteoporosis, Post-Operative Pain, Rectal Cancer, Rheumatoid Arthritis, Solid Tumor, Triple-Negative Breast Cancer (TNBC) and Ulcerative Colitis.

Furthermore, this report also reviews key players involved in Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4)
- The report reviews Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4) targeted therapeutics and enlists all their major and minor projects
- The report assesses Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

【レポートの目次】

Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4) – Overview
Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4) – Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4) – Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4) – Companies Involved in Therapeutics Development
ARTham Therapeutics Inc
AskAt Inc
Eisai Co Ltd
Eli Lilly and Co
GlaxoSmithKline Plc
Kaken Pharmaceutical Co Ltd
Mesentech Inc
NB Health Laboratory Co Ltd
Ono Pharmaceutical Co Ltd
RaQualia Pharma Inc
Rottapharm Biotech Srl
Shanghai Haishi Biopharmaceutical Co Ltd
Sosei Heptares
Tempest Therapeutics Inc
Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4) – Drug Profiles
AAT-008 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ARTEP – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CR-6086 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
E-7046 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
grapiprant – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GSK-726701A – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
KAG-308 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ONO-4578 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
P-001 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RMX-1002 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Agonize EP4 Receptor for Osteoporosis and Osteogenesis Imperfecta – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Antagonize EP4 Receptor for Inflammatory Pain – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Target Prostanoid EP4 Receptor for Inflammatory Bowel Disease – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Antagonize Prostanoid EP2 and EP4 Receptors for Endometriosis – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TPST-1495 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4) – Dormant Products
Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4) – Discontinued Products
Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4) – Product Development Milestones
Featured News & Press Releases
Sep 30, 2019: Adlai Nortye presents encouraging phase 1b study data of AN0025 (an Oral EP4 Antagonist) for locally advanced rectal cancer at ESMO 2019
May 07, 2019: Kyn Therapeutics strengthens leadership team with key appointments
Dec 20, 2018: Kyn Therapeutics and Merck begin Phase Ib/I trials of ARY-007
Jul 19, 2018: Investigational New Drug (IND) Application for EP4 antagonist AAT-007 for Oncology Is Approved in China
Apr 17, 2018: Japan Patent Office Granted AskAt a Cartilage Disease Use Patent of EP4 Antagonist
Jan 22, 2018: Investigational New Drug (IND) Application for EP4 antagonist AAT-007 for Oncology Filed in China
Jan 22, 2018: Investigational New Drug (IND) Application for EP4 antagonist AAT-007 for Oncology Filed in China
Dec 18, 2017: Investigational new drug application for EP4 antagonist AAT-007 was approved by the National Food and Drug Administration of the People’s Republic of China
Sep 01, 2017: Autoimmune disease Use Patent for EP4 antagonist Approved in Korea
Sep 01, 2017: Eisai to Present Abstract on E7046 at ESMO 2017 Congress
Sep 01, 2017: Eisai to Present Abstract on its Oncology Product Candidate E7046 at the ESMO 2017 Congress
Jun 30, 2017: India Patent Office Granted AskAt a Substance Patent of EP4 antagonist(AAT-007)
Apr 25, 2017: Autoimmune disease Use Patent for EP4 antagonist Approved in Japan
Mar 30, 2017: Treatment of Cancer Use Patent for EP4 antagonist Approved in US
Aug 17, 2016: Treatment of Cancer Use Patent for EP4 antagonist Approved in China
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Indications, H2 2019
Number of Products under Development by Indications, H2 2019 (Contd..1), H2 2019
Number of Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Products under Development by Companies, H2 2019 (Contd..2), H2 2019
Number of Products under Investigation by Universities/Institutes, H2 2019
Products under Investigation by Universities/Institutes, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Pipeline by ARTham Therapeutics Inc, H2 2019
Pipeline by AskAt Inc, H2 2019
Pipeline by Eisai Co Ltd, H2 2019
Pipeline by Eli Lilly and Co, H2 2019
Pipeline by GlaxoSmithKline Plc, H2 2019
Pipeline by Kaken Pharmaceutical Co Ltd, H2 2019
Pipeline by Mesentech Inc, H2 2019
Pipeline by NB Health Laboratory Co Ltd, H2 2019
Pipeline by Ono Pharmaceutical Co Ltd, H2 2019
Pipeline by RaQualia Pharma Inc, H2 2019
Pipeline by Rottapharm Biotech Srl, H2 2019
Pipeline by Shanghai Haishi Biopharmaceutical Co Ltd, H2 2019
Pipeline by Sosei Heptares, H2 2019
Pipeline by Tempest Therapeutics Inc, H2 2019
Dormant Projects, H2 2019
Discontinued Products, H2 2019
Discontinued Products, H2 2019 (Contd..1), H2 2019

【掲載企業】

ARTham Therapeutics Inc
AskAt Inc
Eisai Co Ltd
Eli Lilly and Co
GlaxoSmithKline Plc
Kaken Pharmaceutical Co Ltd
Mesentech Inc
NB Health Laboratory Co Ltd
Ono Pharmaceutical Co Ltd
RaQualia Pharma Inc
Rottapharm Biotech Srl
Shanghai Haishi Biopharmaceutical Co Ltd
Sosei Heptares
Tempest Therapeutics Inc

★調査レポート[プロスタグランジンE2受容体EP4サブタイプ治療薬市場:パイプラインレビュー(2019年下半期)] (コード:GDATA20MY0150)販売に関する免責事項を必ずご確認ください。
★調査レポート[プロスタグランジンE2受容体EP4サブタイプ治療薬市場:パイプラインレビュー(2019年下半期)]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆